These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 35551568)
1. Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis. Fabiano G; Marcellusi A; Mennini FS; Sciattella P; Favato G Eur J Health Econ; 2023 Feb; 24(1):75-80. PubMed ID: 35551568 [TBL] [Abstract][Full Text] [Related]
2. The costs of treating vaginal and vulval cancer in England (2009-2015). Stephens S; Chatterjee A; Coles V; Crawford R BMC Public Health; 2020 Apr; 20(1):453. PubMed ID: 32252711 [TBL] [Abstract][Full Text] [Related]
3. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Insinga RP; Dasbach EJ; Elbasha EH Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547 [TBL] [Abstract][Full Text] [Related]
4. The economic burden of human papillomavirus-related precancers and cancers in Sweden. Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012 [TBL] [Abstract][Full Text] [Related]
5. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study. Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028 [TBL] [Abstract][Full Text] [Related]
6. Economic burden of HPV9-related diseases: a real-world cost analysis from Italy. Mennini FS; Fabiano G; Favato G; Sciattella P; Bonanni P; Pinto C; Marcellusi A Eur J Health Econ; 2019 Aug; 20(6):829-840. PubMed ID: 30900047 [TBL] [Abstract][Full Text] [Related]
7. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination. Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189 [TBL] [Abstract][Full Text] [Related]
8. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. Ginindza TG; Sartorius B; Dlamini X; Östensson E PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205 [TBL] [Abstract][Full Text] [Related]
9. The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018. Chesson HW; Laprise JF; Brisson M; Martin D; Ekwueme DU; Markowitz LE Sex Transm Dis; 2021 Apr; 48(4):278-284. PubMed ID: 33492104 [TBL] [Abstract][Full Text] [Related]
10. The healthcare costs of treating human papillomavirus-related cancers in Norway. Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346 [TBL] [Abstract][Full Text] [Related]
11. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477 [TBL] [Abstract][Full Text] [Related]
12. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada. Righolt CH; Pabla G; Mahmud SM Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769 [TBL] [Abstract][Full Text] [Related]
13. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015. Ki M; Choi HY; Han M; Oh JK Vaccine; 2018 Jul; 36(31):4633-4640. PubMed ID: 29961603 [TBL] [Abstract][Full Text] [Related]
14. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221 [TBL] [Abstract][Full Text] [Related]
15. Economic burden of human papillomavirus-related diseases in Italy. Baio G; Capone A; Marcellusi A; Mennini FS; Favato G PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412 [TBL] [Abstract][Full Text] [Related]
16. Spectrum of genital human papillomavirus infection in a female adolescent population. Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107 [TBL] [Abstract][Full Text] [Related]
17. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687 [TBL] [Abstract][Full Text] [Related]
18. Health and economic burden of HPV-related diseases in Singapore. Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Annemans L; Rémy V; Oyee J; Largeron N Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343 [TBL] [Abstract][Full Text] [Related]
20. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]